Cunte Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8968656/publications.pdf

Version: 2024-02-01

	007	1040018	940516
20	287	9	16
papers	citations	h-index	g-index
20	20	20	105
20	20	20	195
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Expression patterns of immune checkpoints in acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 28.	17.0	100
2	Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia. Frontiers in Pharmacology, 2020, 11, 582955.	3.5	21
3	Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma. Experimental Hematology and Oncology, 2021, 10, 20.	5.0	21
4	Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia. Biomarker Research, 2021, 9, 17.	6.8	18
5	Predictive value of TCR \hat{V}^2 - \hat{J}^2 profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight, 2022, 7, .	5.0	17
6	Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin–proteasome pathway. Journal of Leukocyte Biology, 2022, 112, 919-929.	3.3	16
7	Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 740642.	2.8	15
8	Age-Related Immune Profile of the T Cell Receptor Repertoire, Thymic Recent Output Function, and miRNAs. BioMed Research International, 2020, 2020, 1-13.	1.9	10
9	High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia. Hematology, 2021, 26, 210-214.	1.5	10
10	NRF2 activation induced by PMLâ€RARα promotes microRNA 125bâ€1 expression and confers resistance to chemotherapy in acute promyelocytic leukemia. Clinical and Translational Medicine, 2021, 11, e418.	4.0	9
11	Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome. Biomarker Research, 2021, 9, 46.	6.8	8
12	Poor prognosis of intraâ€tumoural TRBV6â€6 variants in <i>EGFR</i> â€mutant NSCLC: Results from the ADJUVANTâ€CTONG1104 trial. Clinical and Translational Medicine, 2022, 12, e775.	4.0	8
13	TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma. Cancer Cell International, 2021, 21, 490.	4.1	7
14	Higher Expression of <i>WT1</i> With Lower <i>CD58</i> Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia. Technology in Cancer Research and Treatment, 2021, 20, 153303382110521.	1.9	6
15	High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma. Biomarker Research, 2022, 10, .	6.8	6
16	CD8+GITR+ T cells may negatively regulate T cell overactivation in aplastic anemia. Immunological Investigations, 2021, 50, 406-415.	2.0	5
17	The importance of genomic predictors for clinical outcome of hematological malignancies. Blood Science, 2021, 3, 93-95.	0.9	5
18	Physalin B inhibits cell proliferation and induces apoptosis in undifferentiated human gastric cancer HGCâ€⊋7 cells. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 224-231.	1.1	3

#	Article	lF	CITATIONS
19	Abnormal miR-214/A20 expression might play a role in T cell activation in patients with aplastic anemia. Blood Science, 2020, 2, 100-105.	0.9	1
20	Predictive value of intraâ€tumoural TCRβ rearrangements in precisely selecting adjuvant therapy for <i>EGFR</i> â€mutant nonâ€smallâ€cell lung cancer. Clinical and Translational Discovery, 2022, 2, .	0.5	1